Getinge GETI-B.ST
SwedenHealthcare · Medical DevicesNasdaq Estocolmo · SEK
252.20 SEK (+0.9%)
10 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Getinge AB is a Swedish medical technology company that designs and manufactures equipment and solutions for operating rooms, intensive care, and sterilization, selling to hospitals and healthcare systems worldwide.
Listed on Nasdaq Estocolmo · Symbol GETI-B.ST · STO: GETI-B · Currency SEK
Key points
from its scores- ✓Favourable backdrop7.4
- ✓Good share-price trend7.2
- ✓Strong growth7.0
- !Somewhat demanding valuation5.3
- !Average business quality5.9
AI analysis
bottom line, main risk, context and newsEarnings growth is strong and valuation is not demanding, but return on capital and cash conversion limit the upside potential in the short term.
Getinge shows earnings growth of 60.50% with an operating margin of 16.12%, although its ROE of 8.95% and cash conversion of 48.32% suggest moderate return on capital; the valuation (P/E 25.43) is reasonable for the sector, and positive momentum (16.24% over 12 months) reinforces the current trend.
The main risk is dependence on innovation and regulatory approval of new products in a highly competitive sector, where a delay or failure in a key launch could slow earnings growth.
Context and risks
Getinge operates in the medical devices sector, a segment that does not depend on commodities or shipping routes affected by the current geopolitical context. Its net debt is moderate (ND/EBITDA of 1.54) and its business generates stable cash flows, so the rise in interest rates and the strength of the dollar have no material impact on its valuation or financial health.
Is Getinge stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 25.4 | 26.7 | −5% |
| EV / EBITDA | 13.1 | 14.5 | −9% |
| Price / book | 2.2 | 4.1 | −46% |
| Price / sales | 2.0 | 3.4 | −42% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.3 out of 10 (median for Healthcare: 4.7).
Average analyst target: 252.20 SEK, +0.9% versus the price.
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 25.4
- Forward P/E
- 22.9
- EV / EBITDA
- 13.1
- Price / book
- 2.2
- Price / sales
- 2.0
- PEG
- 1.35
- Market cap
- 68.1B SEK
- Enterprise value
- 77.2B SEK
Profitability
- ROE
- 8.9%
- ROA
- 5.2%
- ROIC (approx.)
- 13.1%
- Gross margin
- 48.6%
- Operating margin
- 16.1%
- Net margin
- 7.8%
- Free cash flow
- 2.8B SEK
- FCF yield
- 4.2%
- Cash conversion
- 48%
Solvency
- Total debt
- 11.1B SEK
- Net debt
- 9.0B SEK
- Cash
- 2.1B SEK
- EBITDA
- 5.9B SEK
- Net debt / EBITDA
- 1.54
- Debt / equity
- 35.81
- Current ratio
- 1.31
- Quick ratio
- 0.74
Growth
- Revenue growth
- +1.7%
- Earnings growth
- +60.5%
- EPS (TTM)
- 9.83 SEK
- EPS (forward)
- 10.94 SEK
Dividend
- Dividend yield
- 1.9%
- Payout
- 48.3%
Risk and market
- Beta
- 0.82
- Analyst consensus
- Buy (10)
- Target price
- 252.20 SEK
- 52-week range
- 175.90 – 254.10
Recent news
All GETI-B.ST news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Getinge
Is Getinge stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 5.3 out of 10 (median for Healthcare: 4.7). Average analyst target: 252.20 SEK, +0.9% versus the price. This is not investment advice.
What score does Getinge get on MeridIAn Screener?
It scores 6.4 out of 10, rank 632 of 2,130 (better than 68% of the companies analysed). Its strongest category is Risk & Context (7.4) and its weakest, Valuation (5.3). Analysis of 08/10/2026.
What is Getinge's P/E ratio?
Its P/E is 25.4: the share price equals 25.4 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 22.9.
How much is Getinge worth on the stock market?
Its market capitalisation is 68.1B SEK and its enterprise value, debt included, is 77.2B SEK.
How much debt does Getinge have?
Its net debt (debt minus cash) is 9.0B SEK. That is 1.54 times its EBITDA; the Healthcare median is 1.53.
Does Getinge pay a dividend?
Yes: its dividend yield is 1.90% and it pays out 48% of its earnings.
How has Getinge stock performed over the last year?
It has risen 24.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 175.90 and 254.10 SEK. Past performance does not guarantee future results.
What do analysts think of Getinge?
10 analysts cover it; their average recommendation is “Buy” and their average target is 252.20 SEK (+0.9% versus the price). It is an estimate, not market data.